{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:40:09Z","timestamp":1784202009026,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":819,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.5604\/16652681.1231581","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T11:18:30Z","timestamp":1487848710000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C"],"prefix":"10.1016","volume":"16","author":[{"given":"Jonathan G.","family":"Stine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javelle A.","family":"Wynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Niccum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeral L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.5604\/16652681.1231581_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","article-title":"Hepatitis C virus infection and insulin resistance","volume":"5","author":"Bose","year":"2014","journal-title":"World journal of diabetes"},{"key":"10.5604\/16652681.1231581_bib0010","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatolo-gy"},{"key":"10.5604\/16652681.1231581_bib0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained viro-logic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterolo-gy"},{"key":"10.5604\/16652681.1231581_bib0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2893.2006.00729.x","article-title":"Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C","volume":"13","author":"Greenberg","year":"2006","journal-title":"J Viral Hepatitis"},{"key":"10.5604\/16652681.1231581_bib0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4254\/wjh.v3.i5.99","article-title":"Insulin resistance and chronic liver disease","volume":"3","author":"Kawaguchi","year":"2011","journal-title":"World J Hepatol"},{"key":"10.5604\/16652681.1231581_bib0030","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/jhep.2001.0103306le01","article-title":"Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States","volume":"33","author":"Mehta","year":"2001","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1231581_bib0035","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3748\/wjg.v22.i4.1461","article-title":"Metabolic alterations and hepatitis C: From bench to bedside","volume":"22","author":"Chang","year":"2016","journal-title":"WJG"},{"key":"10.5604\/16652681.1231581_bib0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jgh.12313","article-title":"Chronic hepatitis C infection is associated with insulin resistance and lipid profiles","volume":"30","author":"Dai","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1231581_bib0045","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2337\/diacare.27.5.1171","article-title":"High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury","volume":"27","author":"Lecube","year":"2004","journal-title":"Diabetes Care"},{"key":"10.5604\/16652681.1231581_bib0050","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3748\/wjg.v18.i3.212","article-title":"Hepatitis C virus induced insulin resistance impairs response to antiviral therapy","volume":"18","author":"El-Zayadi","year":"2012","journal-title":"WJG"},{"key":"10.5604\/16652681.1231581_bib0055","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.cgh.2008.03.024","article-title":"Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment","volume":"6","author":"Harrison","year":"2008","journal-title":"Clin Gastroen-terol Hepatol"},{"key":"10.5604\/16652681.1231581_bib0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2036.2011.04716.x","article-title":"Meta-analysis: insulin resistance and sustained virological response in hepatitis C","volume":"34","author":"Eslam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.5604\/16652681.1231581_bib0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C","volume":"48","author":"Romero-Gomez","year":"2008","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1231581_bib0070","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.22269","article-title":"Hepatitis C virus infection: molecular pathways to metabolic syndrome","volume":"47","author":"Sheikh","year":"2008","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1231581_bib0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","article-title":"Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2","volume":"102","author":"Kawaguchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.5604\/16652681.1231581_bib0080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","article-title":"Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients","volume":"50","author":"Dai","year":"2009","journal-title":". J Hepatol"},{"key":"10.5604\/16652681.1231581_bib0085","series-title":"J Hepatol","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","author":"Belli","year":"2016"},{"key":"10.5604\/16652681.1231581_bib0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/apt.13343","article-title":"Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies","volume":"42","author":"Deterding","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.5604\/16652681.1231581_bib0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11894-016-0508-y","article-title":"Virologic cure of hepatitis C: Impact on hepatic fibrosis and patient outcomes","volume":"18","author":"Gonzalez","year":"2016","journal-title":"Current Gastroenterology Reports"},{"key":"10.5604\/16652681.1231581_bib0100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.clinthera.2015.05.503","article-title":"Costs and resource utilization associated with anemia and rash in chronic hepatitis c patients treated with direct-acting antiviral agents in the United States","volume":"37","author":"Le","year":"2015","journal-title":"Clin Ther"},{"key":"10.5604\/16652681.1231581_bib0105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon Alfa-2b\/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1231581_bib0110","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/14740338.2015.1088002","article-title":"The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy","volume":"14","author":"Smith","year":"2015","journal-title":"Expert opinion on drug safety"},{"key":"10.5604\/16652681.1231581_bib0115","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publisherspanel.com\/icid\/pdf\/1231581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:36:01Z","timestamp":1761647761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119303849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1665268119303849"],"URL":"https:\/\/doi.org\/10.5604\/16652681.1231581","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/16652681.1231581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}